COR1167
A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 3-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Subjects with Chronic Heart Failure
- Stage
- inclusie
- Medicine
- COR-1167
- Population
- Hartfalen
- Phase
- I
- First Patient In
- 7 May 2024
- Last Patient In
- 1 February 2026
- Last Patient Last Visit
- -
Inclusion period, 23 days remaining
National Lead
prof. dr. A. Voors
Cardioloog
Board Contact
